Liver Anti-Fibrotic Pipeline 2026: Post-Resmetirom Era

Introduction

In the Spring of 2024, Madrigal Pharmaceuticals' THR-β agonist Resmetirom (Rezdiffra) received accelerated FDA approval, marking a historic milestone as the world's first approved treatment for MASH (Metabolic dysfunction-associated steatohepatitis). In August 2025, Novo Nordisk's Semaglutide (Wegovy) became the second approved MASH therapy — and the first GLP-1 receptor agonist — under FDA accelerated approval. The MASH space has officially entered the "multi-approved-drug era."

However, neither approved agent can powerfully reverse pre-existing severe fibrosis on its own. The focus of MASH drug development for 2025-2026 has therefore expanded rapidly toward anti-fibrotic efficacy — how to directly and powerfully drive fibrosis regression — while metabolic correction, weight loss, and anti-inflammatory mechanisms remain central pillars. Across FGF21 analogues, incretin multi-agonists, and nuclear-receptor / metabolic-pathway targets, 2025-2026 has already delivered a wave of megadeal acquisitions and imminent Phase 3 readouts.

This article explores the most promising liver anti-fibrotics in the 2026 pipeline — 10+ assets across five mechanistic classes — plus the preclinical evaluation strategies required to validate next-generation candidates.

1. The Paradigm Shift Brought by Resmetirom

The achievement of the primary endpoints in Resmetirom's Phase 3 MAESTRO-NASH trial presented two critical facts to the industry¹:

Resolving steatosis prevents fibrosis progression: If lipotoxicity (the root cause of MASH) is reduced early, fibrosis worsening is significantly halted.
However, "Reversal" of existing advanced fibrosis (F3) remains difficult: Despite approval, only about 25% of treated patients met the fibrosis-improvement endpoint (fibrosis improvement without worsening of MASH). The remaining ~75% did not meet the primary criterion — the majority remained stable, with a smaller fraction showing worsening.

Given these outcomes, the future of MASH treatment will likely adopt a personalized combination strategy: controlling early stages (F1-F2) with metabolic modifiers (Resmetirom or Semaglutide-class GLP-1 RAs), while targeting advanced stages (F3-F4) with drugs that possess powerful, direct "anti-fibrotic mechanisms" — either alone or in combination.

For researchers tracking fibrosis & inflammation R&D

FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.

2. 2026 Liver Anti-Fibrotic Pipeline at a Glance

Below is a class-by-class snapshot of approved, in-development, and discontinued assets. Failed programs are included intentionally — "why did it fail" carries substantial learning value for competitors and preclinical strategy alike.

Class	Asset / Sponsor	Phase	Recent milestone	Notes
Approved (THR-β)	Resmetirom / Madrigal	Approved (FDA accelerated)	FDA approval 2024-03-14 (first-ever MASH drug)	F1-F3 target; fibrosis improvement ~25%
Approved (GLP-1)	Semaglutide (Wegovy) / Novo Nordisk	Approved (FDA accelerated)	FDA accelerated approval 2025-08-15 (ESSENCE Ph3)	F2-F3 MASH; MASH resolution 62.9% vs 34.3%
FGF21	Efruxifermin / Akero → acquired by Novo 2025-12-09	Ph3 SYNCHRONY	HARMONY 96-wk 49% fibrosis improvement; SYMMETRY 39% reversal in F4	Deal value up to $5.2B ($4.7B base + $0.5B CVR, F4 MASH approval-contingent)
FGF21	Pegozafermin / 89bio → acquired by Roche 2025-10-30	Ph3 ENLIGHTEN	ENLIVEN Ph2b: 27% fibrosis improvement in F2-F3	Deal value up to $3.5B ($14.50/share + CVR up to $6/share)
FGF21 (monthly)	Efimosfermin (ex-BOS-580) / Boston Pharma → acquired by GSK 2025-07	Ph3-ready	Ph2: 45.2% fibrosis improvement; 67.7% MASH resolution	$1.2B upfront + up to $800M milestones; monthly subcutaneous
GLP-1/GCG	Survodutide / Boehringer Ingelheim + Zealand Pharma	Ph3 LIVERAGE	FDA Breakthrough Oct 2024; Ph3 enrolling	Ph2 NEJM 2024: MASH resolution 62% (4.8mg primary); F2-F3 fibrosis improvement 64.5% (6.0mg post-hoc)
GLP-1/GIP	Tirzepatide / Eli Lilly	Ph3 SYNERGY-NASH expansion	Ph2 SYNERGY-NASH: MASH resolution up to 62%	Already approved in T2D (Mounjaro) / obesity (Zepbound); MASH indication in development
GLP-1/GCG	Pemvidutide / Altimmune	Ph2b complete → Ph3 in 2026	IMPACT 48-wk MASH resolution 59.1% (The Lancet 2025)	Fibrosis improvement ITT not statistically significant; Ph3 design underway
Pan-PPAR	Lanifibranor / Inventiva	Ph3 NATiV3	Enrollment complete 2025-04; topline 2026 Q4	Oral 800/1200 mg; main cohort 1009 + exploratory 410 patients
FASN	Denifanstat / Sagimet	Ph3 FASCINATE-3 + FASCINIT	FDA Breakthrough Oct 2024	Oral QD; FASCINATE-2 Ph2b met MASH resolution / NAS-reduction primaries
SGRM	Miricorilant / Corcept	Ph2b MONARCH	Readout expected late 2026 (NCT06108219, n=175)	Selective glucocorticoid receptor modulator; Ph1b rapid liver-fat reduction
Discontinued (FGF19)	Aldafermin / NGM Bio	Ph3 abandoned	ALPINE 2/3 Ph2b primary miss (2021)	NGM Bio executed 75% layoff 2024, MASH halted; pivoted to PSC
Discontinued (Gal-3)	Belapectin / Galectin Therapeutics	Ph2b/3 primary miss	NAVIGATE primary endpoint missed 2024-12-20	2 mg/kg per-protocol: 48.9% varices reduction; FDA feedback pending

Direct anti-fibrotic targets (CTGF antibody Pamrevlumab, LPA1 antagonist BMS-986020, αvβ6 integrin blockers BG00011 and bexotegrast [PLN-74809]) have accumulated multiple failures, underscoring that "single-agent anti-fibrotic" approaches are considerably harder to validate than combination strategies built on metabolic modulation.

3. Class-by-Class Deep-Dive

A. FGF21 Analogues (Fibroblast Growth Factor 21)

FGF21 is an endocrine hormone that regulates metabolism in the liver and adipose tissue. It improves insulin sensitivity via adiponectin and also exerts direct anti-fibrotic effects by suppressing hepatic stellate cell (HSC) activation. 2025 was defined for MASH by three large FGF21 acquisitions.

Efruxifermin (Akero Therapeutics): Fc-FGF21 fusion protein. HARMONY Ph2b 96-week extension showed 49% ≥1-stage fibrosis improvement versus 19% placebo (The Lancet 2025)². SYMMETRY, evaluating F4 compensated cirrhosis, demonstrated 39% fibrosis reversal (NEJM 2025, Noureddin M et al.)⁶. On 2025-12-09, Novo Nordisk completed acquisition of Akero for $54/share base ($4.7B) + CVR up to $6/share ($0.5B, F4 MASH approval-contingent) = up to $5.2B total. The Phase 3 SYNCHRONY program (Histology / Real-World / Outcomes) reads out across 2026-2027. See Efruxifermin deep-dive.
Pegozafermin (89bio): Pegylated FGF21 analogue. The Phase 2b ENLIVEN trial reported 27% fibrosis improvement without worsening of MASH in F2-F3 patients³. On 2025-10-30, Roche completed the tender offer for 89bio at $14.50/share + CVR up to $6.00/share, totaling up to $3.5B. The Phase 3 ENLIGHTEN program is enrolling MASH patients with advanced fibrosis, including compensated cirrhosis⁷. See Pegozafermin deep-dive.
Efimosfermin (ex-BOS-580, Boston Pharma → GSK): A once-monthly subcutaneous next-generation FGF21 analogue (originated at Novartis → Boston Pharma → GSK). GSK completed acquisition in July 2025 for $1.2B upfront + up to $800M milestones. Phase 2 data: 45.2% fibrosis improvement and 67.7% MASH resolution — comparable to weekly competitors, with monthly dosing as the key differentiator. First launch targeted for 2029⁸.

👉 Potential & Challenges: FGF21 currently leads among metabolic-hormone classes in having clinical data extending to F4 cirrhosis (SYMMETRY F4 cohort: 39% reversal) with strong direct anti-fibrotic action. Key challenges: injectable administration, blood-pressure / IGF-1 elevation, and GI tolerability.

B. Incretin Multi-Agonists (GLP-1 / GCG / GIP)

The largest class by volume. Semaglutide's 2025-08 MASH approval established a clinical foundation that "single-agent GLP-1 can resolve F2-F3 MASH," accelerating next-generation GCG / GIP multi-agonists designed to push incretins all the way to fibrosis reversal.

Semaglutide (Wegovy, Novo Nordisk): FDA accelerated approval 2025-08-15 for non-cirrhotic MASH with moderate-to-advanced (F2-F3) fibrosis. The approval pathway is Accelerated Approval; conversion to Traditional Approval awaits ESSENCE Part 2 confirmatory data. ESSENCE Part 1 achieved MASH resolution 62.9% vs 34.3% and fibrosis improvement 36.8% vs 22.4%⁵. First GLP-1 RA with a MASH indication.
Survodutide (Boehringer Ingelheim + Zealand Pharma co-development): Dual GLP-1 / GCG agonist. In its Phase 2 trial (NEJM 2024), the 4.8 mg/week arm achieved the primary endpoint of MASH resolution in 62% of patients (vs 14% placebo); in the F2-F3 subgroup, the 6.0 mg arm achieved 64.5% fibrosis improvement (vs 25.9% placebo, post-hoc)⁴. FDA Breakthrough Therapy Designation granted October 2024; Phase 3 LIVERAGE is progressing. See Survodutide deep-dive.
Tirzepatide (Eli Lilly): Dual GLP-1 / GIP agonist. Already approved for obesity (Zepbound) and type 2 diabetes (Mounjaro). Phase 2 SYNERGY-NASH demonstrated MASH resolution up to 62% with strong fibrosis-improvement signals; Ph3 expansion is progressing. The "incremental value of the GIP axis" versus Efruxifermin and Survodutide is a focal question.
Pemvidutide (Altimmune): Balanced 1:1 GLP-1 / GCG agonist. IMPACT Phase 2b 48-week data (The Lancet 2025 / AASLD 2025) showed MASH resolution 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001), but fibrosis improvement did not reach statistical significance in the ITT analysis (31.8% / 34.5% vs 25.9%)⁹. Non-invasive markers (ELF, LSM) continued to improve through 48 weeks. Phase 3 program to start in 2026.

C. Nuclear-Receptor and Metabolic-Pathway Targets

Where incretins attack the "metabolic entrance" and FGF21 acts as a "metabolic hormone," this class targets the "metabolic enzymes and transcriptional control." Ph3 readouts cluster in 2026 Q4 – 2027.

Lanifibranor (Inventiva): Oral pan-PPAR (α/δ/γ) agonist. By simultaneously engaging three nuclear receptor isoforms, it targets hepatic steatosis, inflammation, and fibrosis in parallel. Ph2b produced prominent outcomes across MASH resolution and fibrosis improvement in F2-F3. Phase 3 NATiV3 (NCT04849728) completed enrollment 2025-04, topline expected 2026 Q4 (main cohort: 1009 patients, 800/1200 mg, 72 weeks; exploratory cohort: 410 patients)¹⁰. See Lanifibranor deep-dive.
Denifanstat (Sagimet Biosciences): Oral selective FASN (fatty acid synthase) inhibitor. Blocks hepatic de novo lipogenesis directly. Phase 2b FASCINATE-2 met both primary endpoints (MASH resolution / ≥2-point NAS reduction). FDA Breakthrough Therapy Designation granted October 2024. Phase 3 program comprises FASCINATE-3 (biopsy-confirmed F2/F3) and FASCINIT (suspected / confirmed MASLD-MASH with MRI-PDFF primary) — initiated late 2024¹¹. See Denifanstat deep-dive.
Miricorilant (Corcept Therapeutics): Oral, selective glucocorticoid receptor modulator (SGRM). Suppresses hepatic cortisol-driven metabolism to reduce liver fat and fibrosis — a novel mechanism in MASH. Phase 2b MONARCH (NCT06108219, 175 F2/F3 MASH patients) topline expected late 2026¹². Phase 1b suggested rapid liver-fat reduction and improvement in fibrotic markers.

4. The Preclinical Hurdle: Proving Anti-Fibrotic Efficacy

The common requirement for these next-generation pipelines is the ability to "melt" or reverse existing fibrosis. For pharma and biotech companies entering this market, they must prove in the preclinical (animal model) stage that their compound possesses a stronger "anti-fibrotic power" than existing agents like Resmetirom or Semaglutide.

To achieve this, the following evaluation strategies are indispensable:

Selecting the Correct Animal Model: While simple weight-loss drugs can be tested in the GAN DIO model, rapidly screening for direct fibrotic reversal often requires Proof of Concept (PoC) in accelerated fibrosis models such as the CDA-HFD model.
Highly Sensitive Quantitative Evaluation: Relying solely on visual scoring by pathologists (e.g., NAS) is no longer sufficient. Providing absolute quantitative proof of collagen reduction through Sirius Red Staining Image Analysis (% Area) and biochemical Hydroxyproline Assays is becoming a mandatory package for advancing to Phase 2.

5. Conclusion: Toward the Next Frontier of MASH Treatment

The approvals of Resmetirom and Semaglutide are not the "finish line" for the MASH market; they are merely the starting line. Beyond 2026, the developmental spotlight shifts entirely toward "drugs that can safely and powerfully reverse progressive F3/F4 fibrosis." From 2026 Q4 through 2027, major readouts cluster — Efruxifermin Ph3 SYNCHRONY, Lanifibranor NATiV3, Miricorilant MONARCH, Denifanstat FASCINATE-3 — and the three FGF21 megadeals (Novo / Roche / GSK) signal serious big-pharma commitment to the space.

To win this fierce pipeline race, establishing the right "model selection" and "quantitative evaluation systems" to flawlessly prove your compound's anti-fibrotic Mechanism of Action (MoA) during the early preclinical stages is absolutely critical.

Through our CRO partnerships, we provide comprehensive support to accelerate your anti-fibrotic projects, from procuring MASH-specific animal models to conducting fully outsourced quantitative evaluations.

References & Clinical Trials

1. Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PubMed

2. Harrison SA, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8(12):1080-1093. PubMed

3. Loomba R, et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023;389(11):998-1008. PubMed

4. Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. PubMed

5. U.S. Food and Drug Administration. "FDA Approves Treatment for Serious Liver Disease Known as 'MASH'." August 15, 2025. FDA News Release

6. Noureddin M, et al. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (SYMMETRY). N Engl J Med. 2025;392(24):2413-2424. PubMed

7. Roche. "Roche purchases shares in tender offer for 89bio, Inc." October 30, 2025. Roche Press Release

8. GSK. "GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)." July 2025. GSK Press Release

9. Altimmune. "Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025." November 2025. Altimmune IR

10. Inventiva. "Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis." April 2025. NCT04849728. ClinicalTrials.gov

11. Sagimet Biosciences. "Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH." October 2024. Sagimet IR

12. Corcept Therapeutics. MONARCH (NCT06108219): A Phase 2b Study Evaluating Miricorilant in Adult Patients With MASH. ClinicalTrials.gov